FN1 and neoplasm: They found that ASA (a) increases the therapeutic efficacy of GEM by overcoming GEM-resistance and altering the expression of reprogramming factors, (b) inhibits the potential for self-renewal and enhances gemcitabine efficacy, (c) inhibits spheroid formation and aldehyde dehydrogenase isoform 1 (ALDH1) activity, which is defined as a marker for self-renewal capacity, (d) inhibits the development of primary CSC spheroids, (e) inhibits tumor growth and invasion in vivo, and (f) reduces the deposition of extracellular matrix (ECM) components, such as fibronectin and collagen.